X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (620) 620
index medicus (454) 454
secondary hyperparathyroidism (406) 406
calcimimetics (337) 337
male (320) 320
urology & nephrology (307) 307
cinacalcet (293) 293
female (274) 274
hyperparathyroidism (265) 265
parathyroid hormone (264) 264
cinacalcet hydrochloride (260) 260
hyperparathyroidism, secondary - drug therapy (247) 247
calcium-sensing receptor (223) 223
middle aged (219) 219
calcimimetic agents - therapeutic use (218) 218
naphthalenes - therapeutic use (200) 200
calcium (199) 199
parathyroid hormone - blood (196) 196
animals (180) 180
calcimimetic (169) 169
calcium - blood (161) 161
hemodialysis-patients (151) 151
adult (149) 149
aged (147) 147
hyperparathyroidism, secondary - etiology (147) 147
vitamin d (144) 144
hemodialysis (135) 135
treatment outcome (129) 129
parathyroid-hormone (124) 124
parathyroidectomy (124) 124
renal dialysis (119) 119
kidney failure, chronic - complications (118) 118
chronic kidney-disease (112) 112
calcium - metabolism (109) 109
chronic kidney disease (109) 109
pharmacology & pharmacy (108) 108
dialysis (101) 101
receptors, calcium-sensing - metabolism (97) 97
hyperparathyroidism, secondary - blood (94) 94
endocrinology & metabolism (87) 87
nephrology (87) 87
rats (84) 84
hypercalcemia (83) 83
kidney failure, chronic - therapy (83) 83
calcimimetic agent (82) 82
vascular calcification (82) 82
cinacalcet hydrochloride - therapeutic use (81) 81
mineral metabolism (80) 80
transplantation (80) 80
medicine & public health (79) 79
phosphorus (77) 77
disease (72) 72
vitamin-d (71) 71
mortality (68) 68
dialysis patients (67) 67
extracellular ca2+-sensing receptor (67) 67
vitamin d - therapeutic use (67) 67
phosphorus - blood (66) 66
stage renal-disease (65) 65
hyperparathyroidism - drug therapy (63) 63
cinacalcet hcl (61) 61
naphthalenes - pharmacology (60) 60
primary hyperparathyroidism (59) 59
surgery (59) 59
cardiovascular-disease (56) 56
expression (56) 56
naphthalenes - adverse effects (56) 56
renal insufficiency, chronic - complications (56) 56
time factors (56) 56
familial hypocalciuric hypercalcemia (55) 55
kidney diseases (54) 54
renal dialysis - adverse effects (54) 54
risk factors (54) 54
receptors, calcium-sensing - genetics (53) 53
calcimimetic agents - administration & dosage (52) 52
calcimimetic amg-073 (52) 52
chronic kidney failure (52) 52
calcimimetic agents - adverse effects (51) 51
chronic-renal-failure (51) 51
naphthalenes - administration & dosage (50) 50
parathyroid-hormone levels (50) 50
propylamines (50) 50
prospective studies (50) 50
ca2+-sensing receptor (49) 49
calcification (49) 49
calcimimetic agents - pharmacology (49) 49
care and treatment (49) 49
kidney transplantation (49) 49
phosphate (49) 49
phenethylamines (48) 48
pth (47) 47
analysis (46) 46
calcimimetic compound (46) 46
hcl (46) 46
biomarkers - blood (45) 45
hypercalcemia - drug therapy (45) 45
physiological aspects (45) 45
receptors, calcium-sensing - agonists (45) 45
retrospective studies (44) 44
therapy (44) 44
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (856) 856
French (27) 27
German (21) 21
Spanish (18) 18
Japanese (12) 12
Polish (8) 8
Czech (6) 6
Italian (5) 5
Swedish (2) 2
Chinese (1) 1
Portuguese (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Drug Metabolism and Disposition, ISSN 0090-9556, 08/2016, Volume 44, Issue 8, pp. 1319 - 1331
Journal Article
Journal Article
JAMA, ISSN 0098-7484, 01/2017, Volume 317, Issue 2, pp. 156 - 164
IMPORTANCE: Secondary hyperparathyroidism contributes to extraskeletal calcification and is associated with all-cause and cardiovascular mortality. Control is... 
MEDICINE, GENERAL & INTERNAL | CALCIUM-SENSING RECEPTOR | PEPTIDE AGONIST | EVOLVE TRIAL | CARDIOVASCULAR-DISEASE | MINERAL METABOLISM | BONE | CHRONIC KIDNEY-DISEASE | AMG 416 VELCALCETIDE | FGF23 | DIALYSIS | Calcimimetic Agents - administration & dosage | Nausea - chemically induced | Cinacalcet Hydrochloride - pharmacology | Humans | Middle Aged | Calcium - administration & dosage | Male | Cinacalcet Hydrochloride - administration & dosage | Parathyroid Hormone - blood | Peptides - administration & dosage | Calcium - blood | Time Factors | Calcimimetic Agents - pharmacology | Cinacalcet Hydrochloride - adverse effects | Female | Double-Blind Method | Hyperparathyroidism, Secondary - drug therapy | Administration, Oral | Biomarkers - blood | Calcimimetic Agents - adverse effects | Peptides - pharmacology | Kidney Failure, Chronic - therapy | Hyperparathyroidism, Secondary - blood | Vomiting - chemically induced | Fibroblast Growth Factors - blood | Kidney Failure, Chronic - complications | Infusions, Intravenous | Hyperparathyroidism, Secondary - etiology | Peptides - adverse effects | Renal Dialysis | Complications and side effects | Usage | Care and treatment | Parathyroid hormone | Hemodialysis | Dosage and administration | Research | Cinacalcet | Hyperparathyroidism | Patient safety | Endocrine system | Hyperthyroidism | Clinical outcomes
Journal Article
JAMA, ISSN 0098-7484, 01/2017, Volume 317, Issue 2, pp. 146 - 155
Journal Article
Journal Article
Annual Review of Medicine, ISSN 0066-4219, 01/2001, Volume 52, pp. 203 - 220
The discovery, characterization, and cloning of the calcium-sensing receptor (CaR) in 1993 was soon followed by the creation of a new type of drug, the... 
calcimimetic
Journal Article
The Cochrane database of systematic reviews, ISSN 1469-493X, 2014, Volume 12, Issue 12, p. CD006254
Journal Article
Pediatric Nephrology, ISSN 0931-041X, 10/2012, Volume 27, Issue 10, pp. 1953 - 1959
Journal Article
Journal Article
Clinical Journal of the American Society of Nephrology, ISSN 1555-9041, 2015, Volume 10, Issue 1, pp. 98 - 109
Background and objectivesElevated parathyroid hormone levels may be associated with adverse clinical outcomes in patients on dialysis. After the introduction... 
ESRD | dialysis | MORTALITY | parathyroid hormone | PERITONEAL-DIALYSIS | hyperparathyroidism | DIALYSIS OUTCOMES | CALCIUM | CARDIOVASCULAR-DISEASE | UROLOGY & NEPHROLOGY | PARATHYROID-HORMONE | MINERAL METABOLISM | RENAL REPLACEMENT | CHRONIC KIDNEY-DISEASE | CKD | PRACTICE PATTERNS | Hyperparathyroidism, Secondary - therapy | Up-Regulation | Naphthalenes - adverse effects | Prospective Studies | Parathyroidectomy - adverse effects | Humans | Middle Aged | Male | Parathyroid Hormone - blood | Renal Insufficiency, Chronic - complications | Renal Insufficiency, Chronic - therapy | Renal Dialysis - mortality | Time Factors | Renal Insufficiency, Chronic - mortality | Adult | Female | Parathyroidectomy - mortality | Renal Insufficiency, Chronic - diagnosis | Dietary Supplements - adverse effects | Parathyroidectomy - trends | Risk Assessment | Risk Factors | Treatment Outcome | Biomarkers - blood | Calcimimetic Agents - adverse effects | Calcimimetic Agents - therapeutic use | Renal Insufficiency, Chronic - blood | Vitamin D - adverse effects | Hyperparathyroidism, Secondary - blood | Cinacalcet Hydrochloride | Hyperparathyroidism, Secondary - diagnosis | Hyperparathyroidism, Secondary - mortality | Renal Dialysis - adverse effects | Aged | Vitamin D - therapeutic use | Hyperparathyroidism, Secondary - etiology | Naphthalenes - therapeutic use | Original
Journal Article